With more than 49 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 9th SCI/RSC symposium on kinases will encompass plenary lectures on emergent topics and case studies of ongoing programmes as well as successful past programmes. A range of topics including new screening approaches, brain penetrant kinase inhibitors, induced protein degradation, allosteric inhibitors and kinase inhibition for immuno-oncology will be covered, along with views and perspectives on the future of kinase inhibitor research.
This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.
This event will bring together industrial and academic experts representing many of the leading institutions in kinase drug discovery, to discuss a selection of new and emerging topics within the fields of kinase therapeutics for oncology and non-oncology therapies, and foster discussions within the wider industry through networking events such as poster sessions and industrial exhibitions.
The full programme will be announced in due course. Please visit https://www.maggichurchouseevents.co.uk/bmcs/ for further details.
Discounted rates will be offered to SCI and RSC members, and some student bursaries will be available. Further details can be found at https://www.maggichurchouseevents.co.uk/bmcs/.
Exhibition and Sponsorship
There will be a relevant trade exhibition. Further details can be found at https://www.maggichurchouseevents.co.uk/bmcs/.
- John Cumming, F Hoffmann-La Roche
- John Harris, CJH Consultants
- Pascal Savy, Charles River Laboratories
- Mihiro Sunose, Sygnature Discovery
- Richard Ward, AstraZeneca
- Douglas Williamson, Vernalis Research
Tel: +44 (0)1359 221004